ISR News and Press, IsoRay Inc. From 09/17/20

IsoRay, Inc. (ISR) Q4 2020 Results Conference Call September 17, 2020 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Ed Woo - Ascendiant Capital Swayampakula Ramakanth - H.C. Wainwright Presentation...

IsoRay (NYSEMKT: ISR ) : FQ4 GAAP EPS of -$0.02 misses by $0.01 . More news on: IsoRay, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RICHLAND, Wash., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year e...

RICHLAND, Wash., Sept. 16, 2020 (GLOBE NEWSWIRE) --   Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...

RICHLAND, Wash., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June...

RICHLAND, Wash., June 17, 2020 (GLOBE NEWSWIRE) --   Isoray, Inc. (NYSE American: ISR) today announced that it has entered into a research grant agreement with the University of Cincinnati Physicians Company for a study involving the treatment of recurrent head and neck cancers. Uni...

RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal ...

IsoRay, Inc. (ISR) Q3 2020 Earnings Conference Call May 12, 2020 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants Jason Kolbert - Dawson James Ed Woo - Ascendiant Capital William Urschel - Accord Partners...

The U.S. Centers for Medicare and Medicaid Services (CMS) has approved 64 billing codes for reimbursement of IsoRay's (NYSEMKT: ISR ) brachytherapy Cesium-131, allowing hospitals to bill Medicare and private insurers for specific surgical procedures that include the cancer treatment. Mor...

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR) today announced that the Centers for Medicare and Medicaid Services (CMS) has approved 64 ICD-10-PCS billing codes used for reimbursement of Cesium-131 (Cesium Blu™) for the hospital in-patient DR...